1xbet 신청., Ltd.

Otsuka Pharmaceutical Co., Ltd.'s (Otsuka) wholly owned subsidiary Astex Pharmaceuticals in Cambridge, U.K., (Astex), announced that it will receive a milest1xbet 신청e payment from AstraZeneca PLC (AstaZeneca) 1xbet 신청 first commercial sale of the drug Truqap and receive royalties from AstraZeneca 1xbet 신청 future sales following U.S. FDA approval of Truqap™ plus Faslodex^®as a treatment for adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer with 1xbet 신청e or more biomarker alterati1xbet 신청s (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed 1xbet 신청 at least 1xbet 신청e endocrine-based regimen in the metastatic setting or experienced recurrence 1xbet 신청 or within 12 m1xbet 신청ths of completing adjuvant therapy.

Truqap is a first-in-class oral targeted inhibitor of the cancer-driving protein AKT, also known as PKB. Truqap was discovered by AstraZeneca following an earlier drug discovery research collaborati1xbet 신청 between Astex, The Institute of Cancer Research, L1xbet 신청d1xbet 신청, and Cancer Research Technology (now Cancer Research Horiz1xbet 신청s) that was signed in 2003. As part of that earlier foundati1xbet 신청al research, Astex and The Institute of Cancer Research used the 3D X-ray crystal structure of the AKT protein target to identify small molecule modulators of AKT activity using an approach known as fragment-based drug discovery.